ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Galapagos and Gilead Sciences are joining to develop filgotinib, a Galapagos-discovered JAK1-selective inhibitor that has completed Phase II clinical trials for inflammatory indications such as arthritis. Galapagos will receive $725 million in licensing fees and equity investment and could receive up to $1.4 billion in milestone payments. In 2012, AbbVie paid Galapagos $120 million for rights to filgotinib but in September announced that it would advance a different arthritis compound instead.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter